Informatics Publishing Limited

Manigandan Thiruppathy ¹, D. Pavani ², A. Amudhan ¹, T. A. Sarumathi ¹, V. T. Hemalatha ³

Affiliations
1 Department of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, BIHER, Pallikaranai, IN
2 Department of Conservative Dentistry and Endodontics, Sathyabama Dental College and Hospital, Semmanchery, IN
3 Department of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, BIHER, Pallikaranai, Chennai, Tamil Nadu 600100, IN

Abstract

Dentists come across various medically compromised patients. Patients who are under anticoagulant and/ or antiplatelet drugs should be taken into consideration as they are at a high risk to have increased bleeding tendency during minor oral surgical procedures. The substances, which prevent or prolong coagulation of blood, are called Anticoagulants1. The most commonly used medications for oral anticoagulant therapy are Warfarin, Acenocoumarol. The novel oral anticoagulants (NOACs) or directly acting oral anticoagulants [DOACs] were developed with more pharmacokinetic and pharmacodynamic relationships, faster onset of action, and fewer potential interactions. The Novel anticoagulants include Dabigatran Rivaroxaban, Apixaban, Edoxaban.

Keywords

Novel Anticoagulants, Dabigatran, Apixaban.

Full Text